Showing results (1-10 of 59) with videos related to

Sort By:
Pageof 6
Translational Cancer Research|October 15, 2016
The STAMPEDE trial: paradigm-changing data through innovative trial designBradley C Carthon, Emmanuel S Antonarakis
International Journal of Surgical Pathology|July 13, 2021
A Contemporary Clinicopathologic Analysis of Primary Urothelial Carcinoma of the Urethra Without Concurrent Renal Pelvic, Ureteral, or Bladder CarcinomaFengming Chen, Shreyas Joshi, Bradley C Carthon, et al.
Pathology, Research and Practice|August 30, 2021
Primary urothelial carcinoma of the ureter without concurrent renal pelvic or bladder carcinoma: A contemporary clinicopathologic analysisChristina M Gutierrez, Bradley C Carthon, Shreyas Joshi, et al.
BJU International|September 24, 2013
Epidermal growth factor receptor-targeted therapy in locally advanced or metastatic squamous cell carcinoma of the penisBradley C Carthon, Chaan S Ng, Curtis A Pettaway, et al.
Molecular and Cellular Biology|January 20, 2005
Genetic replacement of cyclin D1 function in mouse development by cyclin D2Bradley C Carthon, Carola A Neumann, Manjusri Das, et al.
The Canadian Journal of Urology|June 21, 2013
Therapeutic options for a rising PSA after radical prostatectomyBradley C Carthon, David M Marcus, Lindsey A Herrel, et al.
Cancers|December 23, 2022
Prognostic Evaluation of Metastatic Castration Resistant Prostate Cancer and Neuroendocrine Prostate Cancer with [68Ga]Ga DOTATATE PET-CTMehmet Asim Bilen, Akinyemi Akintayo, Yuan Liu, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|November 28, 2014
Nomograms incorporating serum C-reactive protein effectively predict mortality before and after surgical treatment of renal cell carcinomaWayland Hsiao, Lindsey A Herrel, Changhong Yu, et al.
The Canadian Journal of Urology|December 12, 2012
Salvage therapy for locally recurrent prostate cancer after radiationDavid M Marcus, Daniel J Canter, Ashesh B Jani, et al.
Therapeutic Advances in Medical Oncology|January 25, 2021
Safety and efficacy of extended dosing intervals of denosumab in patients with solid cancers and bone metastases: a retrospective studyAseala I Abousaud, Meagan S Barbee, Christine C Davis, et al.
Pageof 6